[NCI CIRB]S1400: Lung-MAP, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
This study includes genetic testing of your tumor sample and chemotherapy. The purpose of the genetic testing is to see if your tumor has features that certain study drugs used in this trial are designed to work against. After the genetic testing and additional tests, you will receive a study drug and/or a drug that is part of the usual treatment for your type of cancer. This study will help the investigators know whether taking the study drug is the better, the same, or worse than the usual treatment. It will also help the investigators know if genetic testing can identify participants who will or will not benefit from treatment.
Squamous cell non-small cell lung cancer
1. Advanced (stage IIIB or stage IV) squamous cell non-small cell lung cancer
2. Participants must have received one regimen of chemotherapy. The chemotherapy must have included a platinum containing drug.
3. At least 18 years old
4. If your tumor has already been genetically tested, a known mutation in your EGFR gene or an ALK gene fusion makes you ineligible for the study.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Participants will have clinic visits and take study drug until their can
Knight Information Line - firstname.lastname@example.org or 503-494-1080
If patients consent to the optional S1400GEN study during the screening/pre-screening consent they will be compensated with a one time $20 amazon gift card. The gift card will be is distributed by Fred Hutchinson Cancer Center.